VYNE Therapeutics (VYNE) Shares Outstanding (2016 - 2026)

VYNE Therapeutics' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $42.8 million for Q2 2025.

• Quarterly Shares Outstanding (Entity) changed 0.41% year-over-year to $42.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $42.8 million (changed 0.41% YoY) and the FY2024 annual result came in at $42.6 million, up 314.57% from the prior year.
• Shares Outstanding (Entity) was $42.8 million for Q2 2025 at VYNE Therapeutics, roughly flat from $42.7 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $42.8 million in Q2 2025 and bottomed at $2.9 million in Q1 2021.
• A 5-year average of $16.7 million and a median of $3.3 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 1201.66% — and 2025, when it increased 0.22%.
• VYNE Therapeutics' Shares Outstanding (Entity) stood at $3.0 million in 2021, then advanced by 8.5% to $3.2 million in 2022, then surged by 218.08% to $10.3 million in 2023, then soared by 314.57% to $42.6 million in 2024, then increased by 0.4% to $42.8 million in 2025.
• Business Quant data shows VYNE's Shares Outstanding (Entity) at $42.8 million in Q2 2025, $42.7 million in Q1 2025, and $42.6 million in Q4 2024.